Menu
Recruiting NCT07632716

Intensive Care Outcome Prediction Using Admission Carbohydrate-deficient Transferrin

— Observational Intensive Care (ICU) Critical Illness Alcohol Misuse

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Carbohydrate-Deficient Transferrin (CDT) Measurement.
Who it may be relevant to
Registry conditions: Intensive Care (ICU), Critical Illness, Alcohol Misuse. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Austria
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Unsure about the terms? Read our patient guide →

Official title

IMPACT - Intensive Care Outcome Prediction Using Admission Carbohydrate-deficient Transferrin A Prospective Single-center Cohort Study

Overview

The goal of this observational study is to learn whether hazardous alcohol consumption, measured objectively by carbohydrate-deficient transferrin (CDT) levels at intensive care unit (ICU) admission, is associated with worse outcomes in critically ill patients. The main question it aims to answer is: Do elevated CDT levels at ICU admission predict increased short-term mortality and adverse clinical outcomes in adult non-traumatic ICU patients? Participants admitted to the intensive care unit via the emergency department will have CDT levels measured as part of the study. Researchers will then collect and analyze clinical data, including mortality, duration of mechanical ventilation, delirium, ICU length of stay, renal replacement therapy, and ICU readmission rates, during hospitalization and follow-up.

Interventions

  • Diagnostic test Carbohydrate-Deficient Transferrin (CDT) Measurement
    Carbohydrate-deficient transferrin (CDT) measurement is performed at ICU admission as an objective biomarker of sustained hazardous alcohol consumption during the previous 1-3 weeks. CDT values are obtained from routinely collected blood samples in adult non-traumatic ICU patients admitted via the emergency department. The study is purely observational and does not involve administration of a therapeutic intervention or changes to standard clinical care. CDT levels are analyzed in relation to ou

Primary outcome measures

  • The primary outcome of the study is 30-day all-cause mortality in ICU patients. [Time frame: From ICU admission to 30 days after ICU admission]
Secondary outcome measures (7)
  • In-hospital mortality [Time frame: From hospital admission to hospital discharge evaluated 6 Months after study inclusion]
  • ICU length of stay [Time frame: From ICU admission to ICU discharge evaluated 6 Months after study inclusion]
  • Duration of mechanical ventilation [Time frame: From initiation of mechanical ventilation to successful discontinuation during ICU stay evaluated 6 Months after study inclusion]
  • Illness severity score [Time frame: Evaluated from the documentation 6 Months after study inclusion]
  • Illness severity score [Time frame: Evaluated from the documentation 6 Months after study inclusion]
  • Illness severity score [Time frame: Evaluated from the documentation 6 Months after study inclusion]
  • Illness severity score [Time frame: Evaluated from the documentation 6 Months after study inclusion]

Eligibility criteria

Inclusion criteria

  • all patients ≥ 18 admitted to the Department of Emergency Medicine and subsequently transferred to an in-house intensive care unit (ICU)

Exclusion criteria

  • Patients transferred to other hospital departments prior to completion of intensive care
  • Patients admitted directly to the ICU without passing the ED
  • Patients admitted to intermediate care units
  • Patients with pre-existing or newly diagnosed hepatic cirrhosis
  • Patients with known or obvious pregnancy will be excluded.
  • Patients with no vascular access

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Observational model
Cohort

Study locations

Austria · 1 center
  • Medical University of Vienna — Vienna

Identifiers

NCT: NCT07632716 · 1302/2026

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗